Additionally, metformin was found to possibly underlie its ability to prevent the development of lung cancer by reducing circulating levels of IGF-I and insulin and mediate its effects through inhibition of the IGF-I/insulin receptor signaling and receptor tyrosine kinases (RTK) signal pathways [33, 34]. Here, NTRK1 is linked to lung cancer.